Pharmacokinetics and Metabolism of the Anti-Inflammatory Agent Voltaren

Rieß, W.; Stierlin, H; Degen, P.H.; Faigle, J. W.; Gérardin, A.; J, Moppert; Sallmann, A; Schmid, Karl; Schweizer, A.; Šulc, Miloslav; Theobald, W; Wagner, Juergen

doi:10.3109/03009747809097212

Cited by 165 publications

(73 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Diclofenac is used mainly as an oral preparation and less often by the intramuscular or rectal routes (Riess et al, 1978). Diclofenac is relatively potent compared with other NSAIDs and plasma concentrations of the order of 100 ng ml-' are associated with therapeutic effect (Liauw et al*, 1985).…”

Section: Introductionmentioning

confidence: 99%

Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease.

Radermacher

Scholl

et al. 1991

Brit J Clinical Pharma

134

View full text Add to dashboard Cite

1 Ten patients with bilateral knee joint effusions were treated topically with a gel containing 1 g diclofenac/100 g (80 mg three times daily). They were randomized to receive diclofenac gel to one knee and a placebo gel preparation to the other knee. 2 Diclofenac was assayed in synovial fluid and blood plasma by GC/ECD as the pentafluorobenzyl-ester derivative. 3 Total concentrations of diclofenac in synovial fluid (day 4) were significantly higher in the diclofenac gel treated knee than in the contralateral placebo treated knee (25.5 ± 3.6 ng ml-1 vs 21.6 ± 2 ng ml-1; P < 0.05). These concentrations were lower than total plasma drug concentrations (40.6 ± 4.7 ng ml-', n = 10, P < 0.01). Unbound concentrations of diclofenac in synovial fluid from either the diclofenac gel treated or the placebo treated knee were not significantly different from each other or from plasma free concentrations (115 ± 16 and 99 ± 12 vs 108 ± 19 pg ml-'). 4 Clinical parameters showed improvement of joint mobility and a small reduction of swelling (circumference) in both knees with time. However, the differences between knees were not significant. 5 We conclude that direct transport of diclofenac from the skin into the ipsilateral knee joint after cutaneous application is minimal. Distribution seems to be predominantly via the blood. Whether the observed improvements of clinical parameters were due to drug effects or to the spontaneous course of the underlying disease cannot be distinguished.

show abstract

Section: Introductionmentioning

confidence: 99%

Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease.

Radermacher

Scholl

et al. 1991

Brit J Clinical Pharma

134

View full text Add to dashboard Cite

show abstract

“…In an in vivo experimental study, diclophenac sodium has been reported to have a stronger anti-inflammatory effect than ketoprofen (25). Furthermore, a metabolite of diclophenac has also shown to have a marked anti-inflammatory action, much greater than that exerted by other NSAIDs (26,27). Our lower pain scores and fewer tramadol consumptions in patients receiving diclophenac may be attributable to a stronger anti-inflammatory effect of diclophenac than that of other NSAIDs.…”

Section: Discussionmentioning

confidence: 57%

A Comparative Study of the Efficacy of IV Dexketoprofen, Lornoxicam, and Diclophenac Sodium on Postoperative Analgesia and Tramadol Consumption in Patients Receiving Patient-Controlled Tramadol

Kılıçkaya¹,

Güleç²,

Ünlügenç³

et al. 2015

Turk J Anesth Reanim

View full text Add to dashboard Cite

“…Согласно результатам предыдущих исследований концентрация диклофенака натрия достигала максиму-ма после внутримышечного введения через 15 [9] и 25 мин [10]. По нашим данным, пик концентрации после приема калиевой соли диклофенака в виде саше отме-чался раньше (через 10 мин у 7 обследованных и через 15 мин у 17), а уже через 5 мин концентрация диклофенака составляла 38% от Сmax.…”

Section: обсуждение и заключениеunclassified

Pharmacokinetics of diclofenac potassium after oral administration of sachets and tablets

Марцо¹,

Monti²,

Кривелли³

et al. 2008

Modern Rheumatology Journal

View full text Add to dashboard Cite

Диклофенак (2(2,6 дихлоро-анилино)фенилацетиловая кислота, CAS 15307-86-5) -нестероидный противовоспа-лительный препарат, используемый для купирования боли и лечения воспалительных процессов различной локализации (рис. 1) [1].Существует множество фармацевтических форм дикло-фенака, благодаря чему его можно применять перорально, ректально, внутримышечно или местно. Препарат предста-влен в виде свободной кислоты, натриевой и калиевой соли, причем калиевая соль диклофенака гораздо лучше раство-ряется в воде [1,2].Цель исследования -сравнительный анализ фармако-кинетических показателей и изменений во времени сыворо-точной концентрации калиевой соли диклофенака, после перорального приема в дозе 50 мг в форме саше или табле-ток, покрытых сахарной оболочкой. Дизайн исследования: две формы препарата, перекрестное исследование с двумя периодами при однократном введении препарата.

show abstract

Pharmacokinetics and Metabolism of the Anti-Inflammatory Agent Voltaren

Cited by 165 publications

References 2 publications

Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease.

Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease.

A Comparative Study of the Efficacy of IV Dexketoprofen, Lornoxicam, and Diclophenac Sodium on Postoperative Analgesia and Tramadol Consumption in Patients Receiving Patient-Controlled Tramadol

Pharmacokinetics of diclofenac potassium after oral administration of sachets and tablets

Contact Info

Product

Resources

About